Item 8.01 Other Events

On January 13, 2020, Zynerba Pharmaceuticals, Inc. (the "Company") issued a press release announcing the achievement of its enrollment target for the Company's Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder) trial of Zygel for the treatment of pediatric and adolescent patients with autism spectrum disorder. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

On January 13, 2020 the Company also issued a press release announcing that enrollment is nearing completion in the Company's pivotal CONNECT-FX (Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X) trial of Zygel in children and adolescents with Fragile X syndrome and providing updates regarding its product pipeline. A copy of this press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.

On January 13, 2020, the Company posted on its website a slide presentation, which is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

Item 9.01 Financial Statements and Exhibits

The following exhibits are being filed herewith:





(d) Exhibits



Exhibit
No.                           Document
  99.1       Press Release, dated January 13, 2020
  99.2       Press Release, dated January 13, 2020
  99.3       Zynerba Pharmaceuticals, Inc. Presentation

© Edgar Online, source Glimpses